STUDY SEARCH RESULTS

1 study found for your search request:  4830-002

Pembrolizumab with Chemotherapy and MK-4830 for Treating Participants with Ovarian Cancer (MK-4830-0...
Condition: High-grade serous ovarian carcinoma, Ovarian carcinoma
Minimum Age: 18 years, Maximum Age: N/A
Gender: Female
Study ID: NCT05446870
Status: Completed
Has Results




Copyright © 2026 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site